- Home
- BRT vs PRQR Comparison
BRT vs PRQR Comparison
Compare BRT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | PRQR |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRT | PRQR |
|---|---|---|
| Price | $14.72 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $19.75 | $8.14 |
| AVG Volume (30 Days) | 60.4K | ★ 566.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,001,000.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $1.07 |
| 52 Week High | $19.01 | $3.10 |
Technical Indicators
Market Signals| Indicator | BRT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 46.46 |
| Support Level | $14.33 | $1.92 |
| Resistance Level | $14.87 | $2.28 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 55.65 | 42.50 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.